Sputum eosinophilia and the short term response to in haled mometasone in chronic obstructive pulmonary disease

Brighhing, C. F.; Mckenna, S.; Hargado, B.; Birring, S.; Green, R.; Siva, R.; Berry, M.; Parker, D.; Monteiro, W.; Pavord, I. D.; Bradcling, P.
March 2005
Thorax;Mar2005, Vol. 60 Issue 3, p193
Academic Journal
Background: An association between the sputum eosinophil count and the response to a 2 week course of prednisolone has previously been reported in patients with chronic obstructive pulmonary disease (COPD). Whether the response to inhaled corticosteroids is related to the presence of eosinophilic inflammation is unclear. Methods: A randomised, double blind, crossover trial of placebo and mometasone furoate (800 μg/day), each given for 6 weeks with a 4 week washout period, was performed in subjects with COPD treated with bronchodilator therapy only. Spirometric tests, symptom scores, chronic respiratory disease questionnaire (CRQ), and induced sputum were performed before and after each treatment phase. Results: Ninety five patients were recruited of which 60 were randomised. Overall there were no treatment associated changes in forced expiratory volume in 1 second (FEV1), total CRQ, or sputum characteristics. After stratification into tertiles by baseline eosinophil count, the net improvement in post-bronchodilator FEV1 increased with mometasone compared with placebo progressively from the least to the most eosinophilic tertile. The mean change in post-bronchodilator FEV1 with mometasone compared with placebo in the highest tertile was 0.111 (95% CI 0.03 to 0.19). This improvement was not associated with a fall in the sputum eosinophil count. Conclusions: An increased sputum eosinophil count is related to an improvement in post-bronchodilator FEV1 following treatment with inhaled mometasone in COPD, but the improvement is not associated with a reduction in the sputum eosinophil count.


Related Articles

  • Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Sin, D. D.; Wu, L.; Anderson, J. A.; Anthonisen, N. R.; Buist, A. S.; Burge, P. S.; Calverley, P. M.; Connett, J. E.; Lindmark, B.; Pauwels, R. A.; Postma, D. S.; Soriano, J. B.; Szafranski, W.; Vestbo, J. // Thorax;Dec2005, Vol. 60 Issue 12, p992 

    Background: Clinical studies suggest that inhaled corticosteroids reduce exacerbations and improve health status in chronic obstructive pulmonary disease (COPD). However, their effect on mortality is unknown. Methods: A pooled analysis, based on intention to treat, of individual patient data...

  • Safety of Inhaled Budesonide. Christensson, Camilla; Thorén, Anders; Lindberg, Bengt // Drug Safety;2008, Vol. 31 Issue 11, p965 

    Inhaled corticosteroid (ICS) therapy is central to the long-term management of asthma and is extensively used in the management of chronic obstructive pulmonary disease (COPD). While administration via inhalation limits systemic exposure compared with oral or injected corticosteroids and,...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease.  // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article focuses on the effects of commonly used treatments for chronic obstructive pulmonary disease on patient outcomes. In patients with chronic obstructive pulmonary disease, long-acting (LA) β[sub 2]-agonists and inhaled corticosteroids, with and without LA β[sub 2]As, reduce...

  • Review: inhaled corticosteroids do not reduce mortality but increase pneumonia in COPD. Rees, P. John // Evidence Based Medicine;Jun2009, Vol. 14 Issue 3, p8 

    The article offers information on the advantages and disadvantages of inhaled corticosteroid (ICS) therapy in treating patients with stable chronic obstructive pulmonary disease (COPD). It notes that inhaled cortecosteroids with placebo or inhaled medications can contribute to mortality,...

  • Review: Long-acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease: COMMENTARY. Rees, P. John // ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p58 

    This article covers a wide range of treatments for chronic obstructive pulmonary disease (COPD). Breadth is achieved at the expense of detail, but the authors provide a useful overview. A major criticism of respiratory medicine has been the absence of large, long-term studies, unlike the field...

  • Inhaled cortico-steroids and COPD exacerbations.  // Infectious Disease Alert;Apr2010 Primary Care, p8 

    The article discusses research done by R. Agarwal and colleagues on inhaled corticosteroids versus placebo for preventing chronic obstructive pulmonary disease (COPD) exacerbations, published in a 2010 issue of "Chest."

  • Primary eosinophilic lung diseases. Rose, David M.; Hrncir, David E. // Allergy & Asthma Proceedings;Jan/Feb2013, Vol. 34 Issue 1, p19 

    Eosinophilic lung diseases typically present as a triad of pulmonary symptoms, ah abnormal chest radiograph, and elevated levels of eosinophils in the sputum and lung tissue. This article focuses on primary causes of eosinophilic lung disease including acure eosinophilic pneumonia, chronic...

  • Simplified detection of eosinophils in induced sputum. Fireman, Elizabeth; Toledano, Brenda; Buchner, Nina; Stark, Moshe; Schwarz, Yehuda // Inflammation Research;Aug2011, Vol. 60 Issue 8, p745 

    Objective and design: The induction of sputum is a safe, noninvasive method of studying airway inflammation in asthma, but the method of analyzing the samples is laborious and requires well-trained technicians using highly specialized laboratory equipment. We introduce a shorter and simpler...

  • Mometasone furoate nasal spray plus oxymetazoline nasal spray: Short-term efficacy and safety in seasonal allergic rhinitis. Meltzer, Eli O.; Bernstein, David I.; Prenner, Bruce M.; Berger, William E.; Shekar, Tulin; Teper, Ariel A. // American Journal of Rhinology & Allergy;Mar/Apr2013, Vol. 27 Issue 2, p102 

    Background: Allergic rhinitis (AR) and associated congestion adversely affect patients' lives. The intranasal corticosteroid mometasone furoate nasal spray (MFNS) is effective for AR symptoms including nasal congestion, and the intranasal decongestant oxymetazoline (OXY) is effective against...


Read the Article


Sign out of this library

Other Topics